Gothenburg, June 24, 2021 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company that develops immunooncological treatments focusing on CAR T-cells and oncolytic viruses, announced today that the company has received ATMP-classification (Advanced Therapy Medicinal Product) by the European Medicines Agency (EMA) for ELC-100 (AdVince), an oncolytic virus for the treatment of neuroendocrine tumors.
EMA and its Committee for Advanced Therapies (CAT) have, after reviewing the company's application, concluded that ELC-100 (AdVince) meets the criteria for ATMP-classification and more specifically the group of gene therapies. "The ATMP classification gives us a clear regulatory path for ELC-100 to market," says Margareth Jorvid, board member of Elicera Therapeutics, with many years of experience in regulatory ATMP work and active within the European TOPRA network. ELC-100 is currently undergoing a phase I/II clinical trial for the treatment of neuroendocrine tumors.
The Company’s share (ELIC) is traded on Nasdaq First North Growth Market. G&W Fondkommission has been appointed the Company's Certified Adviser. E-mail: email@example.com, tel: +468-503 000 50.
For further information please contact:
Jamal El-Mosleh, CEO, Elicera Therapeutics AB
Phone: +46 (0) 703 31 90 51
About Elicera Therapeutics AB
Elicera Therapeutics AB is a clinical phase cell and gene therapy company that develops the next generation of immuno-oncology treatments. The work is based on high-profile long-standing research conducted by Professor Magnus Essand's research group at Uppsala University and has resulted in the development of four drug candidates, including two CAR T cells and two oncolytic viruses. In addition, Elicera has developed a technology platform called iTANK that can be used to optimize all CAR T cells in development and activate killer T cells against cancer.
For more information, please visit www.elicera.com